Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 78.8%

Neg 0% Neu 78.8% Pos 0%

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Overweight rating and announces Price Target of $40.